DEFA14A filed Jun 1, 2026 at 17:00 ET
Outlook Therapeutics filed DEFA14A definitive additional proxy materials for its July 16, 2026 Special Meeting. The board recommends voting FOR: (1a) issuance of up to 16,129,033 shares underlying Private Placement Warrants and up to 2,258,064 shares underlying Placement Agent Warrants from an April 2026 registered direct offering; (1b) issuance of up to 2,142,854 shares underlying previously issued common warrants; (2) increasing authorized common shares from 260M to 600M; and (3) a reverse stock split at a ratio between 1:10 and 1:50 at the board's discretion. The massive authorized share increase and reverse split authorization signal the company is preparing for significant future dilution and potential Nasdaq compliance needs.